DEVELOPMENT OF BUSINESS IN THE THIRD QUARTER (VARIATION AT CURRENT RATE)
thousands of euros
1st quarter
2nd quarter
3rd quarter
2015
2016
Var. 16/15
2015
2016
Var. 16/15
2015
2016
Var.
16/15
France
89,584
90,494
+1.0%
76,864
80,469
+4.7%
97,767
98,840
+1.1%
Europe (excluding France)
40,657
43,685
+7.4%
29,943
31,572
+5.4%
50,614
41,273
-18.5%
North America
17,193
16,064
-6.6%
12,894
14,113
+9.5%
16,055
16,020
-0.2%
Other countries
4,622
3,846
-16.8%
3,816
4,061
+6.4%
3,594
3,280
-8.7%
Group total
152,056
154,089
+1.3%
123,517
130,215
+5.4%
168,030
159,413
-5.1%
thousands of euros
1st quarter
2nd quarter
3rd quarter
2015
2016
Var. 16/15
2015
2016
Var. 16/15
2015
2016
Var.
16/15
Non-proprietary Homeopathic Medicines
79,191
80,147
+1.2%
74,354
76,001
+2.2%
73,677
73,913
+0.3%
OTC Specialties
72,880
73,743
+1.2%
49,030
53,719
+9.6%
94,328
85,319
-9.6%
Other
-15
199
-
133
495
+272.2%
25
181
+624.0%
Group total
152,056
154,089
+1.3%
123,517
130,215
+5.4%
168,030
159,413
-5.1%
CUMULATIVE ACTIVITY AS OF THE END OF SEPTEMBER 2016
thousands of euros
2015
2016
Variation at current exchange rates
Variation at constant exchange rates
France
264,215
269,803
+2.1%
+2.1%
Europe (excluding France)
121,214
116,530
-3.9%
-1.0%
North America
46,142
46,197
+0.1%
+0.9%
Other countries
12,032
11,187
-7.0%
-4.3%
Group total
443,603
443,717
+0.0%
+1.0%
thousands of euros
2015
2016
Variation at current exchange rates
Variation at constant exchange rates
Non-proprietary Homeopathic Medicines
227,222
230,061
+1.2%
+1.3%
OTC Specialties
216,238
212,781
-1.6%
+0.3%
Other
143
875
+511.9%
+511.9%
Group total
443,603
443,717
+0.0%
+1.0%
HIGHLIGHTS OF THE THIRD QUARTER
Sales revenue in the third quarter of 2016 was down by 5.1% in comparison to 2015 (the impact of exchange rates is not significant over the period).
Sales are decreasing significantly in Russia and to a lesser extent in Spain and in the Czech Republic. They are increasing in France.
OUTLOOK
The level of activity and profitability of the fiscal year will depend on the seasonal pathology of the fourth quarter.
Our company still continues with the same determination the development of homeopathy in the world.
Our next update: January 26, 2017 at market close, publication of the sales revenue for the year 2016.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA
The group's financial information is online at: www.boironfinance.com
Regulated information
Quaterly financial disclosure:
- Third Quarter Information
Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-46118-cp-boiron_201016.pdf
Receive by email the next press releases of the company by registering on
www.actusnews.com, it′s free
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).
BOIRON 
